Zolgensma First To Be Subject To New German Data Collection Rules
Price & Reimbursement Body Sets Out New Process
The G-BA has explained in more detail the procedures for mandating post-launch evidence generation under new legislation introduced in 2019.
You may also be interested in...
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in move towards increasing biosimilar uptake.
Two products that were under fast-track review at the European Medicines Agency have reverted to standard review timelines – Eiger's lonafarnib and GSK's dostarlimab. The Pink Sheet tracker logs these and other developments relating to the agency's accelerated assessment mechanism.